Dose Ranging Study
Public ClinicalTrials.gov record NCT01802723. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose Ranging Study of the Safety and Efficacy of LIPO-202 Healthy Patients With Subcutaneous Fat in the Periumbilical Area
Study identification
- NCT ID
- NCT01802723
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Neothetics, Inc
- Industry
- Enrollment
- 472 participants
Conditions and interventions
Interventions
- Drug: salmeterol xinafoate Drug
- Drug: Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2013
- Primary completion
- May 31, 2013
- Completion
- Sep 30, 2013
- Last update posted
- Mar 25, 2015
2013
United States locations
- U.S. sites
- 22
- U.S. states
- 7
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| United States, California | Beverly Hills | California | — | — |
| United States, California | Encinitas | California | — | — |
| United States, California | Los Angeles | California | — | — |
| United States, California | San Diego | California | — | — |
| United States, California | Santa Ana | California | — | — |
| United States, Florida | Aventura | Florida | — | — |
| United States, Florida | Clearwater | Florida | — | — |
| United States, Florida | Lake Worth | Florida | — | — |
| United States, Florida | Miami | Florida | — | — |
| United States, Florida | Tampa | Florida | — | — |
| United States, Illinois | Buffalo Grove | Illinois | — | — |
| United States, Illinois | Chicago | Illinois | — | — |
| United States, New York | New York | New York | — | — |
| United States, New York | Smithtown | New York | — | — |
| United States, North Carolina | Chapel Hill | North Carolina | — | — |
| United States, North Carolina | Raleigh | North Carolina | — | — |
| United States, Tennessee | Nashville | Tennessee | — | — |
| United States, Texas | Austin | Texas | — | — |
| United States, Texas | Dallas | Texas | — | — |
| United States, Texas | Fort Worth | Texas | — | — |
| United States, Texas | Houston | Texas | — | — |
| United States, Texas | Plano | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01802723, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2015 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01802723 live on ClinicalTrials.gov.